Central Nervous System Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Central Nervous System

The central nervous system or CNS comprises the brain and spinal cord. It is part of our nervous system and it is termed as central because it is a center that receives information, coordinates it and influences the activity of the whole body. It controls our breathing, thoughts, heart rate, emotions, movement, body temperature, the release of some hormones and other parts as well.

The CNS composed of white and gray matter. This can be found in the brain which is encased by the skull. The outer cortex of the brain contains gray matter and white matter in the tract. White matter works as a connector which connects the various location of nerve cell bodies and carries nerve impulses between neuron. White matter consists of myelinated axons. Gray matter is made of neuropil, neuronal cell bodies, glial cells, synapses, and capillaries. The difference between gray matter and white matter is that the latter contains few myelinated axons and numerous cell bodies, while white matter contains few cell bodies and more long-range myelinated axon tracts.

There are various CNS diseases and conditions. CNS infection causes encephalitis and poliomyelitis, neurological disorders like ADHD, autism, Alzheimer's disease, Parkinson's disease, Multiple Sclerosis (MS), and other, genetic disorders as Krabbe's disease and Huntington's disease.

Sub-tracks:

White and gray matter
Spinal cord
Brain
Cranial nerves
Difference from the peripheral nervous system
Clinical significance

Market Analysis: The global Central Nervous System (CNS) market is set for substantial growth between 2025 and 2030, with projections indicating a reach of USD 254.6 billion by 2030 at a CAGR of 7.7%. This expansion is primarily driven by the escalating global burden of neurological and mental health disorders, a rapidly aging population, and continuous advancements in diagnostics, therapeutics, and drug delivery systems. Key growth areas include CNS drugs (10.12% CAGR) and CNS biomarkers (7.67% CAGR), with neurodegenerative diseases and anticonvulsants both showing high growth at an 11.5% CAGR. While North America held the largest market share in 2024, Asia Pacific is anticipated to be the fastest-growing region with an 11.1% CAGR. The market's momentum is further supported by significant R&D investments, the integration of digital health solutions, and increasing awareness of CNS disorders. Despite this positive outlook, challenges such as the high cost and complexity of drug development, stringent regulatory standards, and reimbursement hurdles persist.

Tracks